Skip to main content
. 2022 Apr 19;126(11):1548–1554. doi: 10.1038/s41416-022-01737-2

Fig. 2. Kaplan–Meier estimates of overall survival probability (final analysis) for first-line trifluridine/tipiracil plus bevacizumab (TT-B; n = 77) and capecitabine plus bevacizumab (C-B; n = 76) in patients with metastatic colorectal cancer who were ineligible for intensive chemotherapy.

Fig. 2

CI confidence interval, HR hazard ratio.